| AiRuiKa (camrelizumab) / HLB Bio Group |
EBAOFC, NCT03919539: Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab |
|
|
| Unknown status | N/A | 40 | RoW | 5hmc testing | Peking University People's Hospital, Peking University, Northwestern University | Drug Resistance to Famitinib and Camrelizumab, Biomarkers for Efficacy and Toxicity | 06/21 | 12/21 | | |
CSSG-02, NCT03997747: Cancer Genome Study Using Samples From Patients Treated on Clinical Trial SHR1020-SHR-1210-II-OS |
|
|
| Completed | N/A | 38 | RoW | cytology specimen | Peking University People's Hospital, Jiangsu HengRui Medicine Co., Ltd., OrigiMed | Osteosarcoma | 10/21 | 12/21 | | |
ChiCTR2100054019: Clinical value and exploration of Apatinib combined with SHR-1210 in perioperative adjuvant treatment of retroperitoneal sarcomas |
|
|
| Recruiting | N/A | 93 | | Apatinib combined with SHR-1210( Before the surgery) ;surgery | Beijing Cancer Hospital / Peking University Cancer Hospital; Peking University Cancer Hospital, Capital Health Development of Special Funding Support | Retroperitoneal Sarcoma | | | | |
ChiCTR2000036618: Precision therapy strategy for osteosarcoma based on molecular typing: a prospective, single-center, one-brachial umbrella phase II exploratory clinical study |
|
|
| Not yet recruiting | N/A | 18 | | Everolimus 5mg qd + Anlotinib 8mg-12mg day 1-21，28-day cycle ;Camrelizumab 3mg/kg + Ipilimumab 1 mg/kg, 21-days cycle ;Palbociclib 125mg day 1-21 + gemcitabine 600mg/m2 day 1,8,15,22, 28-days cycle ;Olaparib 300mg bid day 1-14 + gemcitabine 600mg/m2 day 1,8,15,22, 28-days cycle ;Metformin 2000mg qd + gemcitabine 675mg/m2 day 1,8, docetaxol 900mg/m2 day 8， 21-days cycle | Shanghai General Hospital; Shanghai General Hospital, Project special fund | osteosarcoma | | | | |
ChiCTR2100046099: Clinical trial of an umbrella study of precise treatment of bone and soft tissue sarcoma based on molecular pathways |
|
|
| Recruiting | N/A | 51 | | SHR-1701+Famitinib ;Camrelizumab+SHR-6390 ;SHR-2554 | Affiliated Sixth People's Hospital, Shanghai Jiaotong University; Affiliated Sixth People's Hospital, Shanghai Jiaotong University, self-funded | advanced bone and soft tissue sarcoma | | | | |
